Adams Wealth Management Purchases Shares of 11,914 Bristol Myers Squibb Company $BMY

Adams Wealth Management acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, HoldingsChannel.com reports. The firm acquired 11,914 shares of the biopharmaceutical company’s stock, valued at approximately $551,000.

Several other large investors also recently modified their holdings of the stock. Trifecta Capital Advisors LLC bought a new position in shares of Bristol Myers Squibb during the second quarter worth approximately $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at $25,000. REAP Financial Group LLC increased its position in Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 428 shares during the period. CBIZ Investment Advisory Services LLC lifted its holdings in shares of Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 231 shares in the last quarter. Finally, GKV Capital Management Co. Inc. bought a new stake in shares of Bristol Myers Squibb in the first quarter valued at about $36,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $52.38 on Monday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The stock has a market capitalization of $106.63 billion, a price-to-earnings ratio of 17.69, a price-to-earnings-growth ratio of 8.02 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The company’s 50 day simple moving average is $46.80 and its 200 day simple moving average is $46.93.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same quarter last year, the business posted $1.80 EPS. The company’s revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 83.78%.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of recent research reports. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company raised their target price on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Scotiabank restated a “sector perform” rating and set a $53.00 price objective (up previously from $45.00) on shares of Bristol Myers Squibb in a research note on Thursday, December 4th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Four equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $54.08.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.